 |
|
|
REFERENCES
301.
Lieber CS: Cytochrome P-4502E1: Its physiological
and pathological role. Physiol Rev 77(2):517–544, 1997.
302.
Zima T, Fialova L, Mestek O, et al: Oxidative
stress, metabolism of ethanol and alcohol-related diseases. Biomed Sci 8(1):59–70,
2001.
303.
Saleem MM, Al-Tamer YY, Skursky L, et al: Alcohol
dehydrogenase activity in the human tissues. Biochem Med 31(1):1–9, 1984.
304.
Dow J, Krasner N, Goldberg A: Ethanol oxidizing
enzyme activities in liver disease. Br J Clin Pharmacol 3(3):461–467, 1976.
305.
Panes J, Soler X, Pares A, et al: Influence of
liver disease on hepatic alcohol and aldehyde dehydrogenases. Gastroenterology 97(3):708–714,
1989.
306.
Bosron WF, Li TK: Genetic polymorphism of human
liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism
and alcoholism. Hepatology 6(3):502–510, 1986.
307.
Ehrig T, Bosron WF, Li TK: Alcohol and aldehyde
dehydrogenase. Alcohol Alcohol 25(2–3):105–116, 1990.
308.
Ramchandani VA, Bosron WF, Li TK: Research advances
in ethanol metabolism. Pathol Biol 49(9):676–682, 2001.
309.
Sherman DI, Ward RJ, Warren-Perry M, et al: Association
of restriction fragment length polymorphism in alcohol dehydrogenase 2 gene with
alcohol induced liver damage [comment]. BMJ 307(6916):1388–1390, 1993.
310.
Poupon RE, Nalpas B, Coutelle C, et al: Polymorphism
of alcohol dehydrogenase, alcohol and aldehyde dehydrogenase activities: Implication
in alcoholic cirrhosis in white patients. The French Group for Research on Alcohol
and Liver [comment]. Hepatology 15(6):1017–1022, 1992.
311.
Crabb DW, Edenberg HJ, Bosron WF, et al: Genotypes
for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2(2)
allele is dominant. J Clin Invest 83(1):314–316, 1989.
312.
Thiele GM, Miller JA, Klassen LW, et al: Long-term
ethanol administration alters the degradation of acetaldehyde adducts by liver endothelial
cells. Hepatology 24(3):643–648, 1996.
313.
Shaw S, Rubin KP, Lieber CS: Depressed hepatic
glutathione and increased diene conjugates in alcoholic liver disease. Evidence
of lipid peroxidation. Dig Dis Sci 28(7):585–589, 1983.
314.
Roll FJ, Bissell DM, Perez HD: Human hepatocytes
metabolizing ethanol generate a non-polar chemotactic factor for human neutrophils.
Biochem Biophys Res Commun 137(2):688–694, 1986.
315.
Williams AJ, Barry RE: Superoxide anion production
and degranulation of rat neutrophils in response to acetaldehyde-altered liver cell
membranes. Clin Sci (Lond) 71(3):313–318, 1986.
316.
Lewis KO, Paton A: Could superoxide cause cirrhosis?
Lancet 2(8291):188–189, 1982.
317.
Holt K, Bennett M, Chojkie, M: Acetaldehyde stimulates
collagen and noncollagen protein production by human fibroblasts. Hepatology 4(5):843–848,
1984.
318.
Mezey E: Commentary on the hypermetabolic state
and the role of oxygen in alcohol-induced liver injury. Recent Dev Alcohol 2:135–141,
1984.
319.
Ito D, Ishii H, Kato S, et al: Significance of
alcohol dehydrogenase (ADH) as a marker of hepatic centrilobular injury: A biochemical
and immunohistochemical study. Alcohol Alcohol Suppl(1):523–527, 1987.
320.
Nanji AA, Zakim D: Alcoholic liver disease.
In Zakim D, Boyer TD (eds): Hepatology: A Textbook
of Liver Disease, 3rd ed. Philadelphia, WB Saunders, 1996, pp 891–961.
321.
Oshita M, Takei Y, Kawano S, et al: Endogenous
nitric oxide attenuates ethanol-induced perturbation of hepatic circulation in the
isolated perfused rat liver. Hepatology 20(4 Pt 1):961–965, 1994.
322.
Nanji AA, Greenberg SS, Tahan SR, et al: Nitric
oxide production in experimental alcoholic liver disease in the rat: Role in protection
from injury. Gastroenterology 109(3):899–907, 1995.
323.
Granger DN, Korthuis RJ: Physiologic mechanisms
of postischemic tissue injury. Annu Rev Physiol 57:311–332, 1995.
324.
Carden DL, Young JA, Granger DN: Pulmonary microvascular
injury after intestinal ischemia-reperfusion: Role of P-selectin. J Appl Physiol
75(6):2529–2534, 1993.
325.
Mulligan MS, Smith CW, Anderson DC, et al: Role
of leukocyte adhesion molecules in complement-induced lung injury. J Immunol 150(6):2401–2406,
1993.
326.
McClain C, Hill D, Schmidt J, et al: Cytokines
and alcoholic liver disease. Semin Liver Dis 13(2):170–182, 1993.
327.
Nordmann R: Alcohol and antioxidant systems.
Alcohol Alcohol 29(5):513–522, 1994.
328.
Reinke LA, Kotake Y, McCay PB, et al: Spin-trapping
studies of hepatic free radicals formed following the acute administration of ethanol
to rats: In vivo detection of 1-hydroxyethyl radicals with PBN. Free Radic Biol
Med 11(1):31–39, 1991.
329.
Nanji AA, Griniuviene B, Sadrzadeh SM, et al:
Effect of type of dietary fat and ethanol on antioxidant enzyme mRNA induction in
rat liver. J Lipid Res 36(4):736–744, 1995.
330.
Rosser BG, Gores GJ: Liver cell necrosis: Cellular
mechanisms and clinical implications. Gastroenterology 108(1):252–275, 1995.
331.
Wang JF, Greenberg SS, Spitzer JJ: Chronic alcohol
administration stimulates nitric oxide formation in the rat liver with or without
pretreatment by lipopolysaccharide. Alcohol Clin Exp Res 19(2):387–393, 1995.
332.
Skinner KA, White CR, Patel R, et al: Nitrosation
of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J
Biol Chem 273(38):24491–24497, 1998.
333.
Beckman JS: Protein tyrosine nitration and peroxynitrite
[comment]. FASEB J 16(9):1144, 2002.
334.
Beckman JS: -OONO: Rebounding from nitric oxide
[comment]. Circ Res 89(4):295–297, 2001.
335.
Reiter CD, Teng RJ, Beckman JS: Superoxide reacts
with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J Biol
Chem 275(42):32460–32466, 2000.
336.
Beckmann JS, Ye YZ, Anderson PG, et al: Extensive
nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry.
Biol Chem Hoppe Seyler 375(2):81–88, 1994.
337.
Beckman JS, Beckman TW, Chen J, et al: Apparent
hydroxyl radical production by peroxynitrite: Implications for endothelial injury
from nitric oxide and superoxide. Proc Natl Acad Sci U S A 87(4):1620–1624,
1990.
338.
Lieber CS, Leo MA, Mak KM, et al: Choline fails
to prevent liver fibrosis in ethanol-fed baboons but causes toxicity. Hepatology
5(4):561–572, 1985.
339.
Lauterburg BH, Davies S, Mitchell JR: Ethanol
suppreses hepatic glutathione synthesis in rats in vivo. J Pharmacol Exp Ther 230(1):7–11,
1984.
340.
Quinn PG, Johnston DE: Detection of chronic liver
disease: Costs and benefits. Gastroenterologist 5(1):58–77, 1997.
341.
McCaughan GW, Gorrell MD, Bishop GA, et al: Molecular
pathogenesis of liver disease: An approach to hepatic inflammation, cirrhosis and
liver transplant tolerance. Immunol Rev 174:172–191, 2000.
342.
Chung RT, Jaffe DL, Friedman LS: Complications
of chronic liver disease. Crit Care Clin 11(2):431–463, 1995.
343.
Rakela J, Krowka MJ: Cardiovascular and pulmonary
complications of liver disease. In Zakim D, Boyer,
TD (eds): Hepatology: A Textbook of Liver Disease, 3rd ed. Philadelphia, WB Saunders,
1996, pp 675–685.
344.
Castro M, Krowka MJ, Schroeder DR, et al: Frequency
and clinical implications of increased pulmonary artery pressures in liver transplant
patients. Mayo Clin Proc 71(6):543–551, 1996.
345.
Daoud FS, Reeves JT, Schaefer JW: Failure of
hypoxic pulmonary vasoconstriction in patients with liver cirrhosis. J Clin Invest
51(5):1076–1080, 1972.
346.
Lazaridis KN, Frank JW, Krowka MJ, et al: Hepatic
hydrothorax: Pathogenesis, diagnosis, and management. Am J Med 107(3):262–267,
1999.
347.
Arroyo V, Gines P: Mechanism of sodium retention
and ascites formation in cirrhosis. J Hepatol 17(Suppl 2):S24–28, 1993.
348.
Moreau R: Hepatorenal syndrome in patients with
cirrhosis. Gastroenterol Hepatol 17(7):739–747, 2002.
349.
Moore KP, Wong F, Gines P, et al: The management
of ascites in cirrhosis: Report on the consensus conference of the International
Ascites Club. Hepatology 38(1):258–266, 2003.
350.
Moreau R, Lebrec D: Acute renal failure in patients
with cirrhosis: Perspectives in the age of MELD. Hepatology 37(2):233–243,
2003.
351.
de Franchis R, Primignani M: Natural history
of portal hypertension in patients with cirrhosis. Clin Liver Dis 5(3):645–663,
2001.
352.
Gitlin N: Hepatic encephalopathy. In Zakim D,
Boyer T (eds): Hepatology: A Textbook of Liver Disease, 3rd ed. Philadelphia,
WB Saunders, 1996, pp 605–618.
353.
Vaughan RB, Chin-Dusting JP: Current pharmacotherapy
in the management of cirrhosis: Focus on the hyperdynamic circulation. Expert Opin
Pharmacother 4(5):625–637, 2003.
354.
Geraghty JG, Angerson WJ, Carter DC: Splanchnic
haemodynamics and vasoactive agents in experimental cirrhosis. HPB Surg 8(2):83–87;
discussion 87–88, 1994.
355.
Iwao T, Toyonaga A, Sato M, et al: Effect of
posture-induced blood volume expansion on systemic and regional hemodynamics in patients
with cirrhosis. J Hepatol 27(3):484–491, 1997; see comments.
356.
Silva G, Navasa M, Bosch J, et al: Hemodynamic
effects of glucagon in portal hypertension. Hepatology 11(4):668–673, 1990.
357.
Cerini R, Koshy A, Hadengue A, et al: Effects
of glucagon on systemic and splanchnic circulation in conscious rats with biliary
cirrhosis. J Hepatol 9(1):69–74, 1989.
358.
Moller S, Bendtsen F, Henriksen JH: Vasoactive
substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest
61(6):421–429, 2001.
359.
Moller S, Bendtsen F, Henriksen JH: Splanchnic
and systemic hemodynamic derangement in decompensated cirrhosis. Can J Gastroenterol
15(2):94–106, 2001.
360.
Cahill PA, Redmond EM, Sitzmann JV: Endothelial
dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 89(3):273–293,
2001.
361.
Bomzon A, Blendis LM: Vascular reactivity in
experimental portal hypertension. Am J Physiol 252(2 Pt 1):G158–162, 1987.
362.
Martin PY, Gines P, Schrier RW: Nitric oxide
as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.
N Engl J Med 339(8):533–541, 1998.
363.
Martin PY, Ohara M, Gines P, et al: Nitric oxide
synthase (NOS) inhibition for one week improves renal sodium and water excretion
in cirrhotic rats with ascites [published erratum appears in J Clin Invest 1998 Aug
1;102(3) inside back cover]. J Clin Invest 101(1):235–242, 1998.
364.
Niederberger M, Martin PY, Gines P, et al: Normalization
of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation
in cirrhotic rats. Gastroenterology 109(5):1624–1630, 1995.
365.
Matsumoto A, Ogura K, Hirata Y, et al: Increased
nitric oxide in the exhaled air of patients with decompensated liver cirrhosis.
Ann Intern Med 123(2):110–113, 1995.
366.
Witte CL, Witte MH: Splanchnic circulatory and
tissue fluid dynamics in portal hypertension. Fed Proc 42(6):1685–1689, 1983.
367.
Schrier RW, Abraham WT: Hormones and hemodynamics
in heart failure. N Engl J Med 341(8):577–585, 1999.
368.
Heneghan MA, Harrison PM: Pathogenesis of ascites
in cirrhosis and portal hypertension. Med Sci Monit 6(4):807–816, 2000.
369.
Levy M, Wexler MJ: Renal sodium retention and
ascites formation in dogs with experimental cirrhosis but without portal hypertension
or increased splanchnic vascular capacity. J Lab Clin Med 91(3):520–536, 1978.
370.
Basso D, Fabris C, Plebani M, et al: Alterations
in bilirubin metabolism during extra- and intrahepatic cholestasis. Clinical Investigator
70(1):49–54, 1992.
371.
Kullak-Ublick GA, Meier PJ: Mechanisms of cholestasis.
Clin Liver Dis 4(2):357–385, 2000.
372.
Glasova H, Beuers U: Extrahepatic manifestations
of cholestasis. J Gastroenterol Hepatol 17(9):938–948, 2002.
373.
Trauner M, Fickert P, Stauber RE: Inflammation-induced
cholestasis. J Gastroenterol Hepatol 14(10):946–959, 1999.
374.
Berk PD, Javitt NB: Hyperbilirubinemia and cholestasis,
Am J Med 64(2):311–326, 1978.
375.
Strazzabosco M: Transport systems in cholangiocytes:
Their role in bile formation and cholestasis. Yale J Biol Med 70(4):427–434,
1997.
376.
Shaffer EA: Cholestasis: The ABCs of cellular
mechanisms for impaired bile secretion—transporters and genes. Can J Gastroenterol
16(6):380–389, 2002.
377.
Elferink RO: Cholestasis. Gut 52(Suppl 2):ii42–48,
2003.
378.
Tan LK: Obstetric cholestasis: current opinions
and management. Ann Acad Med Singapore 32(3):294–298, 2003.
379.
Mullally BA, Hansen WF: Intrahepatic cholestasis
of pregnancy: Review of the literature. Obstet Gynecol Surv 57(1):47–52,
2002.
380.
Germain AM, Carvajal JA, Glasinovic JC, et al:
Intrahepatic cholestasis of pregnancy: An intriguing pregnancy-specific disorder.
J Soc Gynecol Investig 9(1):10–14, 2002.
381.
Reyes H, Sjovall J: Bile acids and progesterone
metabolites in intrahepatic cholestasis of pregnancy. Ann Med 32(2):94–106,
2000.
382.
Erlinger S: Drug-induced cholestasis. J Hepatol
26(Suppl 1):1–4, 1997.
383.
Velayudham LS, Farrell GC: Drug-induced cholestasis.
Expert Opin Drug Saf 2(3):287–304, 2003.
384.
Levy C, Lindor KD: Drug-induced cholestasis.
Clin Liver Dis 7(2):311–330, 2003.
385.
Chitturi S, Farrell GC: Drug-induced cholestasis.
Semin Gastrointest Dis 12(2):113–124, 2001.
386.
Malaguarnera M, Santangelo N, Motta M, et al:
Danazol induced cholestasis: Pathogenetic hypothesis. Panminerva Med 39(3):244–247,
1997.
387.
Tung BY, Carithers RL Jr: Cholestasis and alcoholic
liver disease. Clin Liver Dis 3(3):585–601, 1999.
388.
Sandhu IS, Jarvis C, Everson GT: Total parenteral
nutrition and cholestasis. Clin Liver Dis 3(3):489–508, viii, 1999.
389.
Teitelbaum DH, Tracy T: Parenteral nutrition-associated
cholestasis. Semin Pediatr Surg 10(2):72–80, 2001.
390.
Hilzenrat N, Lamoureux E, Sherker A, et al: Cholestasis
in Crohn's disease: A diagnostic challenge. Can J Gastroenterol 11(1):35–37,
1997.
391.
Gilroy RK, Mailliard ME, Gollan JL: Gastrointestinal
disorders of the critically ill. Cholestasis of sepsis. Baillieres Best Pract Res
Clin Gastroenterol 17(3):357–367, 2003.
392.
Hirata K, Ikeda S, Honma T, et al: Sepsis and
cholestasis: Basic findings in the sinusoid and bile canaliculus. J Hepatobiliary
Pancreat Surg 8(1):20–26, 2001.
393.
Moseley RH: Sepsis and cholestasis. Clin Liver
Dis 3(3):465–475, 1999.
394.
Jansen PL: The pathophysiology of cholestasis
with special reference to primary biliary cirrhosis. Baillieres Best Pract Res Clin
Gastroenterol 14(4):571–583, 2000.
395.
Bayraktar Y, Arslan S, Saglam F, et al: What
is the association of primary sclerosing cholangitis with sex and inflammatory bowel
disease in Turkish patients? Hepatogastroenterology 45(24):2064–2072, 1998.
396.
Harrison PM: Prevention of bile duct cancer in
primary sclerosing cholangitis. Ann of Oncol 10(Suppl 4):208–211, 1999.
397.
Casali AM, Carbone G, Cavalli G: Intrahepatic
bile duct loss in primary sclerosing cholangitis: A quantitative study. Histopathology
32(5):449–453, 1998.
398.
van Milligen de Wit AW, van Deventer SJ, Tytgat
GN: Immunogenetic aspects of primary sclerosing cholangitis: Implications for therapeutic
strategies. Am J Gastroenterol 90(6):893–900, 1995.
399.
Luketic VA, Shiffman ML: Benign recurrent intrahepatic
cholestasis. Clin Liver Dis 3(3):509–528, viii, 1999.
400.
Trauner M, Fickert P, Stauber RE: Hepatocellular
bile salt transport: Lessons from cholestasis. Can J Gastroenterol 14(Suppl D):99D–104D,
2000.
401.
Jansen PL, Muller M: Genetic cholestasis: Lessons
from the molecular physiology of bile formation. Can J Gastroenterol 14(3):233–238,
2000.
402.
Knisely AS: Progressive familial intrahepatic
cholestasis: A personal perspective. Pediatr Dev Pathol 3(2):113–125, 2000.
403.
Karpen SJ: Update on the etiologies and management
of neonatal cholestasis. Clin Perinatol 29(1):159–180, 2002.
404.
Emerick KM, Whitington PF: Molecular basis of
neonatal cholestasis. Pediatr Clin North Am 49(1):221–235, 2002.
405.
Thompson R, Strautnieks S: BSEP: Function and
role in progressive familial intrahepatic cholestasis. Semin Liver Dis 21(4):545–550,
2001.
406.
Carulli N, Manenti F, Ponz de Leon M, et al:
Alteration of drug metabolism during cholestasis in man. Eur J Clin Invest 5(6):455–462,
1975.
407.
Richter E, Breimer DD, Zilly W: Disposition of
hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug
metabolism-inducing agents. Eur J Clin Pharmacol 17(3):197–202, 1980.
408.
Miguet JP, Vuitton D, Deschamps JP, et al: Cholestasis
and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine
in patients with intrahepatic or extrahepatic cholestasis. Dig Dis Sci 26(8):718–722,
1981.
409.
Kawata S, Imai Y, Inada M, et al: Selective reduction
of hepatic cytochrome P450 content in patients with intrahepatic cholestasis. A
mechanism for impairment of microsomal drug oxidation. Gastroenterology 92(2):299–303,
1987.
410.
Chen J, Farrell GC: Bile acids produce a generalized
reduction of the catalytic activity of cytochromes P450 and other hepatic microsomal
enzymes in vitro: Relevance to drug metabolism in experimental cholestasis. J Gastroenterol
Hepatol 11(9):870–877, 1996.
411.
Harrison LI, Gibaldi M: Influence of cholestasis
on drug elimination: Pharmacokinetics. J Pharm Sci 65(9):1346–1348, 1976.
412.
Lebrault C, Duvaldestin P, Henzel D, et al: Pharmacokinetics
and pharmacodynamics of vecuronium in patients with cholestasis. Br J Anaesth 58(9):983–987,
1986.
413.
Jenkins JK, Boothby LA: Treatment of itching
associated with intrahepatic cholestasis of pregnancy. Ann Pharmacother 36(9):1462–1465,
2002.
414.
Palma J, Reyes H, Ribalta J, et al: Ursodeoxycholic
acid in the treatment of cholestasis of pregnancy: A randomized, double-blind study
controlled with placebo. J Hepatol 27(6):1022–1028, 1997.
415.
Better OS: Renal and cardiovascular dysfunction
in liver disease [clinical conference]. Kidney Int 29(2):598–607, 1986.
416.
Binah O, Rubinstein I, Bomzon A, et al: Effects
of bile acids on ventricular muscle contraction and electrophysiological properties:
Studies in rat papillary muscle and isolated ventricular myocytes. Naunyn Schmiedebergs
Arch Pharmacol 335(2):160–165, 1987.
417.
Jacob G, Nassar N, Hayam G, et al: Cardiac function
and responsiveness to beta-adrenoceptor agonists in rats with obstructive jaundice.
Am J Physiol 265(2 Pt 1):G314–320, 1993.
418.
Bomzon A, Monies-Chass I, Kamenetz L, et al:
Anesthesia and pressor responsiveness in chronic bile-duct-ligated dogs. Hepatology
11(4):551–556, 1990.
419.
Tamakuma S, Wada N, Ishiyama M, et al: Relationship
between hepatic hemodynamics and biliary pressure in dogs: Its significance in clinical
shock following biliary decompression. Jpn J Surg 5(4):255–268, 1975.
